[Systemic connective tissue diseases--prognostic conclusions of a 30-year study].

Area of Science:

• Rheumatology and Immunology
• Clinical Medicine
• Longitudinal Patient Studies

Context:

• Analysis of 627 patients over three decades with various connective tissue diseases.
• Includes systemic lupus erythematosus, diffuse scleroderma, dermato- and polymyositis, and mixed connective tissue syndrome.
• Evaluation of prognostic factors including disease onset, sex, organ involvement, and therapy.

Purpose:

• To analyze prognostic factors and survival rates in patients with systemic lupus erythematosus, diffuse scleroderma, dermato- and polymyositis, and mixed connective tissue syndrome.
• To assess long-term survival trends over a 30-year period.
• To correlate survival outcomes with disease characteristics and treatment modalities.

Summary:

• Over 90% of patients survived beyond 5 years across all studied connective tissue diseases.
• Ten-year survival rates approached 80% for most conditions, with 15-year survival exceeding 50% for systemic lupus erythematosus and diffuse scleroderma, and 80% for dermato- and polymyositis.
• Significant improvements in survival, more than trebling previous rates, are attributed to effective immunotherapy.

Impact:

• Demonstrates a considerable improvement in the long-term prognosis for patients with these autoimmune diseases.
• Highlights the efficacy of immunotherapy in enhancing patient survival, particularly for systemic lupus erythematosus and dermato- and polymyositis.
• Provides valuable data for clinicians and researchers regarding the evolving management and outcomes of connective tissue diseases.